ArticleSubstance use & misuse2026
Reach of Community-Selected Strategies to Reduce Opioid-Related Overdose Deaths in the HEALing Communities Study.
Article in Substance use & misuse, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04111939 (HEALing Communities Study), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
HEALing Communities Study: Developing and Testing an Integrated Approach to Address the Opioid Crisis
Who cites it
2 citing papers in PubMed.
- Community coalition's diversity and targeted overdose prevention strategies designed to reach special populations.Harm reduction journal · 2026Article
- The role of external and internal context on adoption and implementation of evidence-based practices: a serial case study qualitative analysis of top performers in the HEALing Communities Study.Implementation science communications · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Funding
Abstract
introductionDespite recent declines, the U.S. opioid overdose crisis persists. The HEALing Communities Study (HCS) aimed to reduce opioid overdose deaths through community-level adoption of evidence-based practices (EBPs), including overdose education and naloxone distribution (OEND) and medications for opioid use disorder (MOUD). This paper describes the reach of OEND and MOUD strategies implemented by the 33 HCS wait-list control communities.
methodsWe conducted descriptive statistical analysis of reach data collected from July 2022 through December 2023 to (1) summarize overall EBP implementation and reach and (2) compare the demographic representation of individuals reached to community demographic population estimates.
resultsCommunities implemented 474 EBPs (251 OEND, 223 MOUD), reporting an average reach of 16,482 individuals monthly. For OEND, percent reached exceeded community population representation for individuals aged 18-34 years (40% vs 31%) and 35-54 years (41% vs 31%) and non-Hispanic Black individuals (20% vs 15%). For MOUD, percent reached exceeded the opioid use disorder population representation for individuals aged 35-54 years (58% vs 52%) and non-Hispanic White individuals (88% vs 80%); however, there was lower representation for individuals aged 18-34 years (28% vs 38%) and non-Hispanic Black individuals (6% vs 13%). Distributions by sex were comparable for OEND and MOUD.
conclusionsFindings signal the promise of community-engaged interventions to reach diverse groups with OEND and reflect the challenges of overcoming longstanding barriers to MOUD access. This work provides practical examples for monitoring the reach of EBPs across multiple research sites and communities and for assessing representativeness, a valuable marker of equity. Trial Registration: Clinical Trials.gov http://www.clinicaltrials.gov: Identifier: NCT04111939.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.